Triple Receptor Agonism
Triple receptor agonism describes a single peptide engineered to activate three receptors at deliberately chosen relative potencies. The design question is not whether all three can be hit, but in what ratio.
Key concepts
- Poly-agonism is defined by potency ratio, not total potency
- Opposing signals on glucose handling make balance central
- Potency is normally reported relative to native ligand
- Desensitisation and signalling bias require secondary assays
- Integrated systems such as organoids or perfused organs test net effect, not just receptor activity
- The optimal receptor ratio for a given endpoint is still an open question
- Triple agonism is one point on a spectrum from single-receptor to dual to triple agonist design
- Bias and selectivity are independent properties, both requiring dedicated assay formats
From single agonists to poly-agonists
Peptide design in this field moved in stages: native hormone analogues first, then stabilised single-receptor agonists, then dual agonists combining GIP and GLP-1 activity, and then tri-agonists adding glucagon receptor activity. Each step increased the number of pharmacological variables a single molecule carries.
A poly-agonist is therefore not simply a stronger agonist. It is a molecule whose behaviour depends on the ratio between its activities, which is why published characterisation reports potency at each receptor rather than a single figure.
Why balance matters
Because the three receptors are expressed in different tissues and, in the case of incretin versus glucagon signalling, act in partly opposing directions on glucose handling, the relative potency ratio determines which tissue dominates the net response at a given concentration.
In practical terms, two tri-agonists with identical receptor targets can behave very differently if their potency ratios differ. Comparisons across molecules are only meaningful when the ratio is stated.
Characterising a tri-agonist in vitro
Standard practice is to express each human receptor separately in a defined cell background and measure cAMP accumulation across a concentration range, alongside the native hormone as a reference. That yields three potency values expressed relative to native ligand rather than in absolute terms.
Secondary assays — binding affinity, arrestin recruitment, internalisation, and receptor desensitisation after prolonged exposure — are then used to describe whether activity at one receptor is sustained or rapidly attenuated, which single-point potency values cannot show.
Model systems for poly-agonist research
Below the level of single-receptor cell lines, researchers use co-culture and organoid systems, isolated perfused liver or islet preparations, and whole-animal models to ask how the three signals interact once more than one receptor-bearing tissue is present at once. These systems are harder to control than a transfected cell line but are necessary for questions about net physiological effect rather than isolated receptor activity.
Choosing a system should follow directly from the question being asked: a laboratory testing receptor potency needs a clean single-receptor line, while a laboratory testing an integrated metabolic hypothesis needs a system where the relevant tissues, and their relative receptor densities, are represented.
Open questions in poly-agonist design
It remains an open research question which relative potency ratio between GIP, GLP-1 and glucagon receptors, if any, is optimal for a given endpoint, and whether that optimum is even the same across different endpoints. Published comparisons between molecules with different ratios are informative but rarely definitive, because a difference in outcome could reflect the ratio, the absolute potency, or unrelated differences in pharmacokinetics.
For this reason, claims that a particular ratio is superior should be read as hypotheses supported by the cited study’s specific design rather than as settled pharmacological fact, and should be checked against the primary paper’s methods before being generalised.
Positioning within the incretin peptide class
Triple receptor agonism sits at one end of a spectrum of incretin-based peptide design that also includes single-receptor GLP-1 agonists such as semaglutide and dual GIP/GLP-1 agonism as seen in tirzepatide. Each additional receptor target is a deliberate design choice intended to combine signalling components that, individually, are each associated in the literature with a different piece of metabolic physiology.
Because each receptor added to a molecule changes both the intended pharmacology and the number of off-target considerations that must be characterised, triple agonists require a correspondingly larger preclinical characterisation package than single-receptor molecules before their profile can be compared meaningfully with earlier peptides in the class.
Characterising balance experimentally
Because a triple agonist’s defining property is the ratio of activity across three receptors rather than potency at any one of them, standard practice is to generate a full concentration-response curve at each receptor in a matched assay format and express the result as relative potency against a reference agonist for that receptor. Reporting a single receptor’s potency in isolation, without the other two, does not describe the molecule’s designed pharmacology.
Bias and selectivity are assessed separately using orthogonal assay formats such as beta-arrestin recruitment and receptor internalisation alongside the primary cAMP signalling readout, since a molecule’s G-protein potency and its recruitment of downstream regulatory proteins can diverge and both properties are relevant to a full pharmacological description.
Strength of the current evidence
The design principles here are well established in peptide pharmacology. Which receptor ratio is optimal for any given research endpoint remains unresolved.
References
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022 (PubMed)
- Unimolecular poly-agonist literature (PubMed search listing)
Related Retatrutide research
- GLP-1 Receptor — The GLP-1 receptor: expression, signalling and its role in incretin peptide research.
- GIP Receptor — GIP receptor biology and why GIP activity is included in dual and triple agonist design.
- Glucagon Receptor — Hepatic glucagon receptor signalling and its role in the retatrutide profile.
- Mechanism of Action — How retatrutide engages the GIP, GLP-1 and glucagon receptors, and what that combined signalling is understood to do.
- What is Retatrutide? — Definition, research designation, peptide class and receptor targets of retatrutide as a laboratory research compound.
Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis
Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.